All In Biotech

Drug Trial Radar · NCT00379847

An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia

A 4-day, Open-Label, Multicenter Phase 3b Study of IV YM087 in Patients With Euvolemic or Hypervolemic Hyponatremia

Last checked: Nov 19, 2026Latest source record: May 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 251 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

251

Actual

Start

Feb 2004

Primary completion

Jun 2005

Study completion Jun 2005

Sponsor

Lead sponsor
Cumberland PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Sep 25, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate the application of a vasopressin antagonist in the treatment of hyponatremia most likely caused by inappropriate AVP secretion. The population studied will include patients with euvolemic or hypervolemic hyponatremia.

Conditions

  • Hyponatremia

Interventions

  • conivaptanDrug

    IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Baseline-adjusted change in AUC for serum sodiumTime frame: 96 Hours

Locations

28 sites in 3 countries. Site status is shown where the registry gives one.

  • Site not named

    Tuscon, Arizona

  • Site not named

    Denver, Colorado

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Augusta, Georgia

  • Site not named

    Petoskey, Michigan

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Columbia, South Carolina

  • Site not named

    Afula, Israel

  • Site not named

    Ashkelon, Israel

  • Site not named

    Hadera, Israel

  • 2 Sites

    Haifa, Israel

  • Site not named

    Holon, Israel

  • 2 Sites

    Jerusalem, Israel

  • Site not named

    Nahariya, Israel

  • Site not named

    Rehovot, Israel

  • 2 Sites

    Safed, Israel

  • Site not named

    Tel Aviv, Israel

  • Site not named

    Tsrifin, Israel

  • Site not named

    Amanzimototi, South Africa

  • Site not named

    Bellville, South Africa

  • Site not named

    Bloemfontein, South Africa

  • 2 Sites

    Durban, South Africa

  • 4 Sites

    Johannesburg, South Africa

  • Site not named

    Krugersdorp, South Africa

  • Site not named

    Lyttelton, South Africa

  • Site not named

    Pretoria, South Africa

  • Site not named

    Somerset West, South Africa

  • Site not named

    Soweto, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.